Literature DB >> 10320640

Intravenous granulocyte colony-stimulating factor increases the release of tumour necrosis factor and interleukin-1beta into the cerebrospinal fluid, but does not inhibit the growth of Streptococcus pneumoniae in experimental meningitis.

H Schmidt1, K Stuertz, W Brück, V Chen, A K Stringaris, F R Fischer, R Nau.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) possesses an antimicrobial effect in several animal models of infection. To evaluate a possible effect of G-CSF on the course of pneumococcal meningitis, rabbits infected intracisternally (i.c.) with Streptococcus pneumoniae type 3 (n = 7) received 50 microgram/kg of rhG-CSF intravenously (i.v.) 1 h prior to infection. Seven infected animals served as controls. Uninfected rabbits received 10 microgram of G-CSF (n = 3), 2 microgram G-CSF (n = 3) or saline (n = 3) i.c. G-CSF injected i.c. did not produce cerebrospinal fluid (CSF) leucocytosis. Compared with the control group, i.v. G-CSF given prior to i.c. infection increased the percentage of granulocytes in blood 6 h and 12 h after infection. Twelve hours after infection, CSF tumour necrosis factor (TNF) activity and CSF interleukin (IL)-1beta concentrations were significantly higher in G-CSF-treated animals. G-CSF did not decrease bacterial growth in the subarachnoid space and the CSF leucocyte densities were not influenced. At 24 h after infection, G-CSF did not reduce the CSF concentrations of neurone-specific enolase and the density of apoptotic neurones in the dentate gyrus of the hippocampus. In conclusion, i.v. G-CSF increased the concentration of pro-inflammatory cytokines in the CSF but did not decrease the growth of Streptococcus pneumoniae in the subarachnoid space.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320640     DOI: 10.1046/j.1365-3083.1999.00518.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis.

Authors:  T O'Reilly; C Ostergaard; J Vaxelaire; O Zak
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis.

Authors:  Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Mercedes Valls Seron; Frank Baas; Arie van der Ende; Diederik van de Beek
Journal:  Immunogenetics       Date:  2012-09-30       Impact factor: 2.846

4.  Characterization of a pneumococcal meningitis mouse model.

Authors:  Barry Mook-Kanamori; Madelijn Geldhoff; Dirk Troost; Tom van der Poll; Diederik van de Beek
Journal:  BMC Infect Dis       Date:  2012-03-28       Impact factor: 3.090

5.  Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis.

Authors:  Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Dirk Troost; Jaklien C Leemans; Richard A Flavell; Arie Van der Ende; Tom Van der Poll; Diederik Van de Beek
Journal:  BMC Infect Dis       Date:  2013-07-31       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.